Combination
KLOW Stack
Vendor nickname · no combination trial
KLOW is GLOW with a fourth lyophilized powder in the cake: KPV (α-MSH 11–13). The common advertised SKU is 80 mg at 50/10/10/10. GHK-Cu is still ~62.5% of every draw. Adding KPV does not create a gut, mast-cell, or autoimmune indication.
Components
- GHK-Cu — Gly-His-Lys copper complex. Pickart dermal/matrikine literature and topical cosmetics are the honest file. “4000 genes / reverse biological age” is marketing. I…
- BPC-157 — A 15-amino-acid fragment studied mostly in animal models of tendon, ligament, gut, and vascular repair. Popular in recovery protocols; not approved for human us…
- TB-500 — Synthetic N-acetyl heptapeptide (Ac-LKKTETQ) matching thymosin β4 residues 17–23, the actin-binding loop. Research-chem SKU is this fragment (~889 Da), not the …
- KPV — KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val). Mouse colitis papers (Dalmasso 2008, Kannengiesser 2008) are the evidence base. It is not a Crohn’s or …
Evidence limits (from leaf)
- No combination trial of the four peptides. Titration tables are milligram arithmetic, not a studied schedule.
- This site will not treat IBD or “leaky gut” from a KLOW page.
- Dalmasso 2008 and Kannengiesser 2008 stay on the KPV leaf. They do not describe this bottle.
Verdict
KLOW is a vendor name for GHK-Cu + BPC-157 + TB-500 + KPV. Common advertised SKU is 80 mg at 50/10/10/10. Not a gut-disease drug. KPV is not an IBD indication on this site.
Do the math
Confirm each milligram on the COA, then use the blend calculator. A mixed vial is not a synergy trial.
Blend / stack calculator